Pipeline Chart

Transgene is focused on discovering and developing a broad pipeline of innovative immunotherapies in the areas of cancer and infectious diseases. This pipeline includes both products deriving from Transgene’s internal research, and particularly from its core viral vector technology, and from in-licensing activities.



Collaborative approaches are key in Transgene’s strategy. We participate in exchanges and collaborations with the aim of developing our R&D expertise, our product portfolio, and our processes. Transgene is engaged in several collaborative programs with public and private partners, in France and worldwide.

Clinical collaboration agreements
Bristol-Myers Squibb (TG4010), UC Davis Medical Center (TG4010), Alliance of Merck KGaA, Darmstadt, Germany, and Pfizer (TG4001)

Collaborative research agreements
Servier (improvement of the manufacturing of allogenic CAR-T cells), Randox (SdAb vectorization)

Selection of past and ongoing research collaborations:

ADNA (Advanced Diagnostics for New Therapeutic Approaches), coordinated by Institut Mérieux and supported by BPIfrance, the French public investment bank. The program brings together four companies specialized in diagnostics (bioMérieux and GenoSafe) and therapeutics (Transgene and Genethon) with the global aim of developing personalized medicines for cancer, infectious diseases and genetic diseases.More information on the ADNA program can be found at www.institut-merieux.com.

ONCOVACCINE. Funded by ANR, French National Research Agency, to develop a new generation of oncolytic vaccinia viruses with enhanced therapeutic indices. Project partners are two renowned academic laboratories, IGBMC (UMR7104 CNRS/UdS Inserm U964) and IREBS (UMR 7242).

IMMUNOCAN. FP7-sponsored European program that aims at increasing cooperation in translational research between European countries and China, coordinated by Trangene. The Fudan University Shanghai Cancer Centre (FDUSCC)(China), the University of Copenhagen (Denmark), the IRCCS (Instituto Nazionale dei Tumori) Foundation (Italy) and the Medizinische Hochschule of Hannover (Germany) are also part of this program. IMMUNOCAN activities are conducted in the laboratories of the joint institute for cancer research of the FDUSCC and Institut Mérieux (FDUSCC-IM) in Shanghai.

HELAZYME. Transgene and New England Biolabs (NEB) have been awarded through a joint innovation program co-organized by Alsace BioValley and the Massachusetts Life Sciences Center (MLSC). This “International Collaborative Industry Program” is supported by grants from MLSC and BPIfrance.

Transgene is an active member of two French regional competitive clusters that promote industry collaboration, academic excellence in basic science and university advanced training. Alsace BioValley (http://www.alsace-biovalley.com) is dedicated to therapeutic innovations, and Lyonbiopôle (www.lyonbiopole.org) is focused on infectious diseases, cancer, nutrition, metabolic diseases and neurosciences.

Transgene works in close collaboration with numerous reference clinical centers in France, Europe and worldwide, such as UC David Medical Center (California, USA), Curie Institute (Paris, France), Greater Paris University Hospitals, AP-HP (Paris, France), Centre Léon Bérard (Lyon, Paris), Institut Bergonié (Bordeaux, France), Centre Hospitalier de l’Université de Montréal (Canada), Medizinische Hochshule Hannover (Hanover, Germany), etc.